Efficacy of naloxone in reducing hypoxemia and duration of immobility following focal to bilateral tonic–clonic seizures
Epilepsia Open · 2025-06 · 10 (3) · 880-893
DOI: 10.1002/epi4.70046 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Epilepsia Open, online erschienen am 28.04.2025. Verfasst von Sylvain Rheims und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Functional Neurology and Epileptology, Hospices Civils de Lyon and Lyon 1 University, Lyon, France. Hauptthemen laut MEDLINE: Naloxone, Hypoxia, Narcotic Antagonists, Seizures. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Agence Nationale de la Recherche, Ministère des Affaires Sociales et de la Santé.
Abstract (Originalsprache)
Objective
Evaluating the efficacy of an opioid antagonist, naloxone (NLX), to reduce the severity of post‐ictal hypoxemia and immobility after focal to bilateral tonic–clonic seizures (FBTCS).
Methods
ENALEPSY is a double‐blind placebo (PCB)‐controlled trial conducted in patients with focal epilepsy undergoing long‐term video‐EEG monitoring (LTM). Patients with a FBTCS during LTM were randomized 1:1 to receive intravenous NLX or PCB within the 2 min following the end of FBTCS. After database lock, a discrepancy between the allocated arm and the received treatment was detected, resulting in a 4:1 NLX:PCB ratio. To further explore the efficacy of NLX, we used historical control (HC) data collected in patients included in the REPO 2 MSE study whose characteristics matched those of patients randomized in ENALEPSY. The efficacy of NLX was then assessed versus PCB and versus HC. The primary endpoint was the delay between the end of the seizure and recovery of SpO 2 ≥ 90%. Secondary efficacy outcomes included desaturation nadir and duration of the post‐ictal immobility.
Results
33 patients contributed to the NLX group, 7 to the PCB group, and 43 to the HC group. The proportion of FBTCS type 1 or 3 was 84% in NLX, 100% in PCB, and 84% in HC. NLX did not improve the delay of recovery of SpO 2 ≥ 90% or the desaturation nadir. By contrast, the duration of the post‐ictal immobility differed across groups. The time to mobility recovery within the first 5 min post‐ictal was very similar in the PCB (200.3 ± 215.8 s) and HC (194.4 ± 192.0 s) groups, and significantly shorter in the NLX group (128.9 ± 151.1 s) when compared to HC (Hazard Ratio, 1.84; 95% CI, 1.11–3.05; p = 0.021). Significance NLX did not prevent post‐ictal respiratory dysfunction but might reduce the duration of post‐ictal immobility. Confirmation of this effect and its impact on SUDEP risk will require additional studies. Plain Language Summary Release of endogenous opioids might participate in the severity of post‐ictal hypoxemia and immobility after focal to bilateral tonic–clonic seizures (FBTCS). We conducted a multicenter double‐blind randomized placebo‐controlled trial evaluating the efficacy of an opioid antagonist, naloxone (NLX), administered within 2 min following the end of FBTCS. The efficacy of NLX was further explored with a comparison with historical control. NLX did not improve the delay of recovery or the severity of post‐ictal hypoxemia. Post‐ictal immobility was significantly shorter in the NLX group when compared to historical control. The impact of these results on SUDEP prevention will require additional studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Functional Neurology and Epileptology, Hospices Civils de Lyon and Lyon 1 University, Lyon, France.
- Lyon's Neuroscience Research Center, INSERM U1028/CNRS UMR 5292/Lyon 1 University, Lyon, France.
- Department of Biostatistics, Hospices Civils de Lyon and University of Lyon, Lyon, France.
- Department of Neurology, Hôpital Pellegrin, Bordeaux, France.
- Department of Neurology, University Hospital of Strasbourg, Strasbourg, France.
- Neurology Department, University Hospital of Nancy, Nancy, France.
ORCID-Profile: Sylvain Rheims, Edouard Hirsch, Fabrice Bartolomei, Vincent Navarro, Sébastien Boulogne, Philippe Ryvlin
Förderung
- Agence Nationale de la Recherche
- Ministère des Affaires Sociales et de la Santé
Zitieren
APA
Rheims, S., Chorfa, F., Michel, V., Hirsch, E., Maillard, L., Valton, L., Bartolomei, F., Derambure, P., Navarro, V., Biberon, J., Crespel, A., Nica, A., Martin, M. L., Mazzola, L., Petit, J., Rossero, V., Boulogne, S., Leclercq, M., Bezin, L., …, & ENALEPSY Study Group (2025). Efficacy of naloxone in reducing hypoxemia and duration of immobility following focal to bilateral tonic–clonic seizures. Epilepsia Open, 10(3), 880-893. https://doi.org/10.1002/epi4.70046
Vancouver
Rheims S, Chorfa F, Michel V, Hirsch E, Maillard L, Valton L, et al. Efficacy of naloxone in reducing hypoxemia and duration of immobility following focal to bilateral tonic–clonic seizures. Epilepsia Open. 2025;10(3):880-893. doi:10.1002/epi4.70046
BibTeX
@article{Rheims2025,
author = {Rheims, Sylvain and Chorfa, Fatima and Michel, Véronique and Hirsch, Edouard and Maillard, Louis and Valton, Luc and Bartolomei, Fabrice and Derambure, Philippe and Navarro, Vincent and Biberon, Julien and Crespel, Arielle and Nica, Anca and Martin, Martine Lemesle and Mazzola, Laure and Petit, Jerome and Rossero, Vincent and Boulogne, Sébastien and Leclercq, Mathilde and Bezin, Laurent and Mercier, Catherine and Roy, Pascal and Ryvlin, Philippe and ENALEPSY Study Group, ENALEPSY Study Group},
title = {Efficacy of naloxone in reducing hypoxemia and duration of immobility following focal to bilateral tonic–clonic seizures},
journal = {Epilepsia Open},
year = {2025},
volume = {10},
number = {3},
pages = {880--893},
doi = {10.1002/epi4.70046}
}
EUVIMED